drugset / Trial / NCT00045565

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

NCT00045565

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of arsenic trioxide and radiation therapy in treating patients with newly diagnosed malignant glioma. Drugs such as arsenic trioxide may stop the growth of malignant glioma by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining arsenic trioxide with radiation therapy may kill more tumor cells.

Timeline

Start
2002-10
Primary completion
2008-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject arsenic trioxide Small molecule Intravenous